Anteris Technologies Ltd
Australian Securities ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Anteris Technologies Global Corp (Nasdaq: AVR, ASX: AVR) develops and commercializes innovative medical devices for structural heart disease, focusing on transcatheter aortic valve replacement (TAVR) therapies. The company's lead product, the DurAVR transcatheter heart valve (THV) system, features a single-piece, native-shaped biomimetic design that mimics healthy aortic valve performance to restore natural blood flow; it incorporates proprietary ADAPT anti-calcification tissue technology, which transforms xenograft tissue into durable bioscaffolds and has supported over 55,000 patient implants globally. Additional pipeline efforts include collaboration with v2vmedtech inc on the VClip minimally invasive repair system for mitral and tricuspid valve regurgitation. Founded in 1999 and headquartered in Toowong, Australia, with key operations in Eagan, Minnesota, USA; Malaga, Australia; and Geneva, Switzerland, Anteris serves target markets including the United States, Europe, Australia, Canada, Asia-Pacific, and the Middle East. Recent developments encompass a landmark U.S. initial public offering and Nasdaq listing in December 2024 raising $88.8 million, alongside re-domiciliation to the United States; a $25.2 million private placement in November 2025; FDA approval in November 2025 for the global PARADIGM pivotal trial of DurAVR THV versus commercial TAVR devices, with European regulatory approvals and site activations progressing; presentation of positive one-year DurAVR clinical data at TCT 2025 showing sustained hemodynamic performance; and advancement of the VClip concept lock milestone.
Pennon returns to profit after water bill hikes
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy
Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push
Anteris Announces Results for the First Quarter of 2026
Whirlpool cuts forecast, suspends dividend as Iran war hammers demand
Dow Jones set for flat start as market await Iran response to US peace deal
JD Sports preview: signs of recovery in focus ahead of World Cup
Voyager Technologies narrows loss in Q1 as revenue comes in below expectations
Nasdaq and S&P surge to new records on Iran deal hopes, AMD and Disney gains
Small Cap Watch: Small Ordinaries edges higher as company news flow continues
Anteris treats first US patients in DurAVR pivotal trial
A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market
Tilray Brands’ strong cannabis sales and upbeat outlook keeps Jefferies analysts bullish
GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressure
Smart automation bots and the future of forex trading
Melrose shares drop 12% as guidance disappoints despite strong cash flow beat
Anteris reports US$77.8m 2025 net operating cash outflow as PARADIGM trial gets underway
Anteris flags proposed US$200 million raising, Medtronic commits up to US$90 million strategic investment
Anteris unveils strong 30-day DurAVR® data in 100-patient small-annulus cohort
Amazon returns to US bond market with $12B offering